

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/644,588-Conf. #5265
<i>(Use as many sheets as necessary)</i>				Filing Date	August 20, 2003
Sheet	1	of	1	First Named Inventor	Connie Sanchez
				Art Unit	1614
				Examiner Name	T. E. Betton
				Attorney Docket Number 05432/100M919-US3	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number+Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ +Number+Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
CA	Mischoulon et al., "Strategies for Managing Depression Refractory to Selective Serotonin Reuptake Inhibitor Treatment: A Survey of Clinicians", <i>Can. J. Psychiatry</i> , 45, 476-481 (2000)				
CB	Posternak et al., "Switching Versus Augmentation: A prospective, Naturalistic Comparison in Depressed, Treatment-Resistant Patients", <i>J. Clin Psychiatry</i> , 62, 135-142 (2001)				
CC	Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Depression by the Committee for Proprietary medicinal Products (CPMP) Dated April 25, 2002				
CD	Approval Package of the Center for Drug Evaluation and Research for Citalopram Hydrobromide (trade name: Celexa) dated July 17, 1998 including the Approval Letter, the Approvable Letter and the Final Printed Labelling specification, said documents having been made available to the public by the FDA on July 20, 1998.				
CE	Merck Manual of Diagnostics, Home Edition, pp 438-447 (1997)				

Examiner Signature	Date Considered	
-----------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). ¹See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ²Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.